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Introduction
Colorectal cancer is one of the most common malig-
nancies worldwide and is the second-leading cause of
cancer morbidity among both men and women. In
Poland more than 7000 men and 6000 women are
diagnosed with colorectal cancer every year [1]. 
In the last decade the average survival of patients
diagnosed with metastatic colorectal cancer increased
from 12 to more than 20 months [2-4]. Most of the
patients in this stage of the disease are eligible for sys-
temic therapy. Thanks to the introduction of the mul-
tidrug regimens and targeted therapy (cetuximab, pani-
tumumab, bewacizumab) into the clinical practice, 5-
year survival can be obtained in approximately 15% of
patients [5-7]. The objective response to the first-line
chemotherapy is achieved by 30 to 55% of the patients
(Objective response rate, ORR), while only 5 to 25% of
patients respond to the second line treatment [8]. The
use of oxaliplatin or irinotecan based chemotherapy
regimens as the second-line treatment prolongs overall
survival time by 8 to 12 months [9,10]. Apart from the
abdominal lymph nodes, liver is the most common site
of the tumor spread. About 60% of the patients with
colorectal cancer develop liver metastases and in
approximately 25% of the patients liver is the only site
of dissemination. The median 5-year survival rate fol-
lowing resection of liver metastases exceeds 30%, sug-
gesting that resectability of the metastases is an impor-
tant prognostic factor [11]. In order to increase the
number of patients undergoing resection of liver metas-
tases, two or three drug chemotherapy regimens associ-
ated with targeted therapies are used in the preoperative
and postoperative setting. The mutational analysis of
the KRAS gene is a necessary condition for the therapy
based on the novel drugs like cetuximab or panitu-
mumab, and the KRAS mutation predicts lack of
response to these anti-EGFR antibodies [12-14]. The
clinical benefit of bevacizumab added to chemotherapy
in colorectal cancer is independent of the KRAS muta-
tional status. This molecule may be used in the treat-
ment of patients with a mutation in the KRAS gene 
(m KRAS) and without mutation (wt KRAS) as well
[15]. In this paper we present a rare case of molecular
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differences, regarding KRAS gene mutational status,
between a primary tumor and secondary lesions in 
a patient with metastatic colon cancer.
A case report
A 53-year old woman was admitted to a local GP unit
because of abdominal pain. The ultrasound examina-
tion of the abdomen revealed the presence of metasta-
tic lesions in both lobes of the liver, the biggest lesion
was located in the segment VI/VII, measuring
58×53mm. Computed tomography (CT) confirmed the
presence of liver metastases and also the signs of 
a neoplasmatic infiltration of the colon's splenic flex-
ure. The patient underwent colonoscopy which
revealed infiltration of the splenic flexure. Several
bioptic samples were collected during endoscopic
examination and the diagnosis of adenocarcinoma was
confirmed histologically (adenocarcinoma G2). The
left hemicolectomy connected with and resection of
the pancreatic tail was performed. The histopathologi-
cal report revealed: macroscopically a fragment of the
colon measuring 25 cm with the ulcerated tumor and
the enlarged lymph nodes in the peri-intestinal tissue,
microscopically: moderately differentiated adenocar-
cinoma (adenocarcinoma mucinosum G-2), infiltrating
the entire thickness of the intestinal wall with penetra-
tion into the peri-intestinal adipose tissue (T3) and
obvious vascular invasion. The distal margins were
free of the cancer infiltration. There were no metas-
tases in the lymph nodes (0/8-N0) and the liver dis-
semination was histologically confirmed (metastases
adenocarcinomatosae). Immunohistochemical analysis
revealed EGFR (epidermal growth factor receptor)
expression, with moderate and strong intensity of
EGFR-membranous staining in 70% of the cancer
cells (Fig. 2). 
The KRAS gene mutational analysis, using the
direct sequencing, revealed a mutation in codon 12
(Fig. 1). Final Diagnosis: pT3N0M1-HEP. The serum
levels of tumor markers CEA and CA 19.9 were 3.3
ng/ml and 1041.3 IU/ml respectively. Because of the
difficulties in administering intravenous chemotherapy
the patient received an oral chemotherapy –
capecitabine (dose 1250 mg/m2 × daily for 14 days, the
21-day rhythm of treatment) in the Maria Sklodowska-
Curie Memorial Cancer Center, Warsaw. After admin-
istration of 2 cycles of the chemotherapy, a reduction
of serum CA 19.9 to the level of 354.1 IU/ml was
achieved, and abdominal ultrasonography revealed 
a partial regression of the metastatic lesions (40%).
Due to the observed toxicity – grade 2 palmar-plantar
erythrodysesthesia (hand-foot syndrome), the dose of
capecitabine was reduced to 2×1000 mg/m2. After 5
cycles, there was a further reduction in serum CA 19.9
to the level of 106.1 IU/ml. The computed tomography
of the abdomen and pelvis, performed in December
2007, demonstrated a regression of changes by 40%.
After another 3 cycles of chemotherapy, CT assess-
ment revealed further regression of changes by 10%,
CA 19.9 serum concentration reached 122 IU/ml and
CEA remained within the normal range – 2.5 ng/ml. In
March 2008, an unanatomical liver tumor resection on
the border of segments IV and V was performed, and
the metastases in segments II and VIII were thermoab-
lated. During the surgery a lesion at the liver hilum,
not described in the imaging studies, was found. Post-
operatively, the patient received a second line pallia-
tive chemotherapy: FOLFOX plus bevacizumab
(oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, 5-fluo-
rouracil 400 mg/m2 – a bolus, 5-flourouracyl 600
mg/m2 – 48-hour infusion, bevacizumab 5 mg/kg 
a cycle, repeated every 14 days). The Ca 19.9 serum
concentration before treatment was 457.3 IU/ml. After
2 cycles the level decreased to 230 IU/ml. A tolerance
of treatment was good. The imaging studies performed
after 5 cycles revealed a stabilization of the disease.
During further treatment with oxaliplatin, the allergic
reaction appeared (fever, chills and epigastric pain dur-
ing the drug infusion), the drug dose was reduced and
during the next cycles the dexamethasone pretreatment
was administered. After administration of the next 5
cycles of chemotherapy, the imaging study revealed
resectability of the other liver changes. After 14 cycles
of chemotherapy FOLFOX + bevacizumab, a surgical
treatment of liver metastatic lesions was carried out. 
A resection of a metastatic lesion located in the II 
and III liver segment, with an adequate margin was 
performed. The removed tumor adhered to the hepatic
vein (R1 resection). The postoperative pathological
examination confirmed the diagnosis of metastatic
adenocarcinoma of the colon. Two months after the
surgery, the serum concentration of CA 19.9 was 6032
IU/ml. Re-examination of EGFR expression in the
metastatic liver tumor was performed (tubular adeno-
carcinoma metastaticum), in which no presence of this
receptor was found (negative reaction) (Fig. 2), and
there were no mutations in codons 12 and 13 of the
KRAS gene (Fig. 1). Given the good response to the
first line chemotherapy, an expected result of the beva-
cizumab treatment, no availability of anti-EGFR treat-
ment, the patient received capecitabine in combination
with bevacizumab. The abdominal ultrasound exami-
nation revealed a conglomerate of the lesions in the
left liver lobe measuring 119 × 70mm. After adminis-
tration of 2 cycles of the treatment, a decrease in the
serum level of CA 19.9 to 3025 IU/ml was obtained
and a regression of the liver lesion by 25%. Efficacy
assessment of the chemotherapy was performed after 4
cycles, a general deterioration of clinical status was
observed, the ultrasound examination of the liver
revealed disease progression. The patient received
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irinotecan monotherapy as the forth line treatment. 2
cycles were administered, without providing the thera-
peutic effect. The chemotherapy was terminated.
Patient died in September 2009. Overall survival in the
metastatic stage of disease was 27 months.
Materials and methods
Tumor specimens and histological examination. Tumor speci-
mens were collected from colorectal cancer patient – primary
tumor and related metastatic site in the liver. Tissues were fixed in
buffered formalin for hematoxylin and eosin (H+E) staining. Seri-
al 5 μm-thick sections of the fixed tissue were cut and stained with
H+E. These specimens were used for routine histopathological
examination. Sections of a paraffin block corresponding to one
representative area of the tumor were stained with
haematoxylin/eosin, and the presence of tumor tissue was verified
by an experienced pathologist. Subsequently, tissue samples from
at least three serial sections were macrodissected to ensure that
specimens contained at least 80% tumor cells.
DNA isolation. DNA from paraffin-embedded colorectal tumor spec-
imens was prepared from 10-30 μm sections after macrodissection,
resulting in selection of at least 80% tumor cells. Tumor samples were
extracted with xylene and ethanol to remove paraffin and placed in
1% SDS/proteinase K (10 mg/ml) at 56°C overnight. DNA was iso-
lated using the The NucliSens easyMAG platform (bioMérieux) for
automated nucleic acid extraction.
Analysis of K-RAS mutation. Mutation analysis of KRAS codons
12 and 13 was carried out by direct sequencing of amplified PCR-
products spanning respective codons. DNA was amplified for
KRAS exon 1 using specific primers: forward FS 5'- TCA TTA TTT
TTA TTA TAA GGC CTG CTG – 3', reverse RS 5'-CAA GAT TTA
CCT CTA TTG TTG GAT CA-3'. Polymerase chain reaction
(PCR) was carried out in a total volume of 10 µl contained 2 µl of
the extracted genomic DNA using 1U of Taq DNA polymerase
(EURx Ltd., Gdansk, Poland). The initial denaturing step was at
95°C for 10 min, followed by 36 cycles of denaturing step at 95°C
for 30 s, annealing step at 56°C for 30 s and extension step at 72°C
for 30 s, ending with a final extension step at 72°C for 5 min.
Amplification products were purified using the 
DNA Gel-Out Kit (DNA GDANSK, Gdynia,
Poland). Automated sequencing was carried out using
the Big Dye Terminator Cycle Sequencing kit version
3.1 (Applied Biosystems, Warsaw, Poland). Sequenc-
ing reactions were purified using the ExTerminator Kit
(DNA GDANSK, Gdynia, Poland), and analysed on an
ABI PRISM 377 DNA sequencer (Applied Biosys-
tems, Warsaw, Poland). A wild-type control DNA sam-
ple (without KRAS codon 12 mutation) and a known
mutation sample were included in the experiment. The
mutation was confirmed by sequencing at least two
independent PCR products.
Immunohistochemistry for EGFR. The paraffin-embedded tis-
sues were cut at 5 μm thickness. Immunohistochemical staining of
sections was performed using the immunohistochemical system kit
EGFR pharmDx (Dako Poland), which included proteinase K, per-
oxidase block, EGFR pharmDx monoclonal mouse antibody
(clone 2-18C9), mouse IgG1 negative control reagent, labeled
polymer HRP, DAB+substrate buffer, liquid DAB+chromogen,
DakoCytomation wash solution 10×, and EGFR pharmDx control
slides. The immunostaining was performed according to instruc-
tions supplied by the manufacturer. The controls used for the vali-
dation of EGFR assay were included in EGFR pharmDx: negative
control reagent, positive and negative control cell preparation.
EGFR expression was detected as membranous and/or cytoplasmic
brown staining of neoplastic cells with various intensity. Positivity
for EGFR expression was defined as any membrane staining above
background level. Both the primary and metastatic neoplasm were
considered positive when >1% of the tumor cells had membranous
staining. A specific membrane staining in less than 1% of neoplas-
tic cells was defined as EGFR-negative.
Ethical issues. The KRAS gene mutational status analysis is a pro-
cedure performed routinely and does not require a bioethics com-
mittee approval.
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Fig. 1. Mutations of the KRAS gene. Identification of the somatic
KRAS codon 12 mutant sequence (G → T at nucleotide 35) in 
a primary tumor of colorectal cancer. Sequences are shown in the
reverse direction and the arrow indicates the position of the muta-
tion.
Fig. 2. Epidermal growth factor recep-
tor (EGFR) staining by immunohisto-
chemistry of primary and secondary
colon adenocarcinoma. (A) EGFR
expression – primary colon adenocarci-
noma; (B) EGFR negative – secondary
colon adenocarcinoma to the liver, (C)
control of staining – the immunohisto-
chemical system kit EGFR pharmDx of
the liver cells.
Discussion
Mutations in the RAS genes family (HRAS, NRAS
and KRAS) are the most common oncogenic changes,
that are present in a majority of the human cancers
[16]. Point mutations in the critical coding sequences
of the KRAS gene, identified mainly in codon 12 and
13 [17,18], are observed in approximately 30-45%
cases of primary colorectal cancer [19,20]. Constitu-
tive activation of the RAS protein, as a result of muta-
tions in the KRAS gene, leads to stimulation of the sig-
naling pathways (PI3K/PTEN/AKT and RAF/MEK/
ERK) responsible for cell growth, inhibition of apop-
tosis, differentiation, proliferation of cancer cells,
invasion and metastases [21,22]. Signaling pathways,
activated via the hyperactive RAS protein, become
independent and cannot be controlled at the level of
EGFR [23]. Mutational status of the KRAS gene is a
key predictive factor for response to the monoclonal
antibodies against EGFR [24-26]. Targeted therapy,
based on a direct blocking of the epidermal growth
factor receptor (EGFR) using specific monoclonal
antibodies (cetuximab and panitumumab), leads to the
inhibition of EGFR signaling cascade [27-29]. Results
of the independent clinical trials led to the EMEA
(European Medicines Agency) approval for the use of
cetuximab and panitumumab in the treatment of
patients with metastatic colon cancer [25,29,30].
According to the approval, therapy with the anti-
EGFR antibodies is confined only to the patients with
a positive immunohistochemical EGFR reaction, when
the presence of the KRAS gene mutations is excluded
[31,32]. Subsequently, the retrospective analyzes have
demonstrated the lack of correlation between EGFR
expression status, assessed by immunohistochemical
staining, and response to the therapy [23,30,33].
Recent studies, evaluating the clinical response in
patients with advanced or metastatic colorectal cancer,
showed that the presence of KRAS mutation is associ-
ated with the lack of response to cetuximab [24,33-37].
Patients without mutations in the KRAS gene gain ther-
apeutic benefit from the use of cetuximab [38]. Simi-
larly, the use of panitumumab in patients with the pres-
ence of KRAS mutations, did not bring the expected
therapeutic benefit [24]. 
Patients with the tumors not presenting mutation in
the KRAS gene (KRAS wild type – WT KRAS), show 
a good response to the targeted therapy, effecting in an
increase of progression free survival (PFS) and overall
survival (OS) [24,30]. However, a significant proportion
of patients with the wild-type KRAS (KRAS-WT) shows
little or no response to the anti-EGFR treatment [39].
Clinical-molecular data clearly indicate the existence of
other mechanisms of cancer cells' resistance to the
therapy with anti-EGFR monoclonal antibodies.
Molecular evaluation of the KRAS status in the
metastatic site, instead of the primary tumor, may have
a great clinical significance. The presence of the KRAS
oncogene mutations in the metastatic tumor, in the
absence of mutations in the primary lesion, could at
least partly explain the resistance of cancer cells to the
treatment. 
Until now, few studies comparing the biological
characteristics, in terms of EGFR, AKT and MAPK
protein expression [40], of primary tumors and corre-
sponding metastases, have been conducted [41,42].
Immunohistochemical findings indicate a considerable
diversity of biological processes involved in the neo-
plastic transformation of the primary and metastatic
tumors. Data presented in our case report confirm the
differences in the EGFR expression between the pri-
mary and secondary tumors. Immunohistochemical
studies showed a positive EGFR reaction in the pri-
mary tumor and a lack of EGFR expression in the
metastatic site. Incompatibility is likely due to the sig-
nificant heterogeneity of the tumors in terms of the
EGFR expression. Previous studies assessing the
mutational status of the KRAS gene in the colorectal
cancer, were confined almost exclusively to the analy-
sis of the primary tumors. The few reports assessing 
a degree of compliance of the KRAS mutational status
in the primary and secondary lesions, are insufficient
and vary significantly. Artale et al described a high
compliance of mutations in the KRAS and BRAF genes
in the primary site and distant metastases of colorectal
cancer (92%) [41].The study population comprised of
only 48 patients and the analysis was confined mostly
to the distant lesions. Santini and colleagues analyzed
the degree of conformity of KRAS mutations in pri-
mary tumors and distant metastases in the group of 99
patients, confirming earlier reports of Artale et al [42].
The results of the analysis showed a high rate of com-
pliance of the KRAS mutational status (96%). Only in
four cases, of which three were related to hepatic
metastases, there was a lack of compliance. Similar
studies conducted by Molinari et al, also revealed 
a high-factor of compliance of the KRAS mutational
model [43], although the study included a small group
of patients. Our case report presents a mismatch of the
KRAS mutational status between the primary tumor
and the metastatic site in the liver. Molecular analysis
revealed the presence of mutations in codon 12 of the
KRAS gene (G12D) in the primary tumor and  a lack of
mutationsin the metastatic lesion. Velho et al conduct-
ed an analysis of the incidence of KRAS and BRAF
mutations in a primary site and corresponding metas-
tases to the lymph nodes in the group of 250 patients
with sporadic colorectal cancer [44]. The obtained
results differed significantly from the results presented
by Artale et al. The frequency of the KRAS mutations
in the lymph nodes metastases was significantly high-
er (82.1%) comparing to the primary tumors (55%).
Molecular data provided by Velho et al support the
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hypothesis that cancer cells acquire KRAS mutations in
the early stages of the cancer progression [44]. The pri-
mary tumor is likely to consist of different populations
of tumor cells in terms of the KRAS mutational status.
Tumor cells presenting the KRAS mutations (KRAS-M)
show a higher rate of proliferation, differentiation and
resistance to apoptosis [22]. Only a small percentage of
tumor cells is able to survive a migration and subse-
quently to initiate the development of the secondary
lesions. The M-KRAS cancer cells show a better adap-
tation to the adverse conditions of a migration and col-
onization of the nearby lymph nodes and the distant tis-
sues. A mechanism of the recruitment and clonal selec-
tion of the tumor cells, in terms of the KRAS mutation-
al status, may be an important process, explaining a
value of the KRAS mutation in the metastatic cascade
[45]. The results of these studies may have a great clin-
ical significance, presenting one of the possible mech-
anisms of resistance to anti-EGFR therapy of the
patients with metastatic colon cancer and WT-KRAS.
The presence of KRAS mutations in the metastatic site
may be an important factor, leading to a resistance to
the treatment. A lack of KRAS mutations in the second-
ary tumors, despite the presence of a mutation in the
primary lesion, may become an additional predictive
factor, allowing better selection of patients undergoing
the anti-EGFR therapy. Additional studies, evaluating
the mutational status of the KRAS gene in the second-
ary lesions may be helpful in selection of the patients
eligible for this type of anti-cancer therapy. 
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